Navigation Links
Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
Date:5/20/2008

- Data being presented today at Digestive Disease Week -

CAMBRIDGE, Mass. and NEW YORK, May 20 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX) today announced the presentation of data from a Phase 2b randomized, double-blind, placebo-controlled study assessing the safety and efficacy of linaclotide in patients with chronic constipation (CC). Analysis of these data indicate that linaclotide met its primary endpoint. The study results are being presented today at the Digestive Disease Week conference in San Diego by Anthony Lembo, M.D. of the Beth Israel Deaconess Medical Center in Boston.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

In the four-week study, once-daily doses of linaclotide -- 75 mcg, 150 mcg, 300 mcg, or 600 mcg -- were compared to placebo. The primary endpoint was the change from pre-treatment in weekly spontaneous bowel movement (SBM) frequency. During the two-week pre-treatment period, the mean baseline weekly SBM frequency rate for the intent-to-treat (ITT) population (n = 307) across all treatment groups was 2.3. Patients in the ITT population who received once-daily dosing of linaclotide demonstrated a statistically significant change in weekly SBM frequency of 2.6 (75 mcg, p < 0.05), 3.3 (150 mcg, p < 0.01), 3.6 (300 mcg, p < 0.001), and 4.3 (600 mcg, p < 0.001) compared to 1.5 for patients receiving placebo. Increases in SBM frequency were dose-related. At all doses above 75 mcg, linaclotide-treated patients also experienced statistically significant improvements in complete spontaneous bowel movement (CSBM) frequ
'/>"/>

SOURCE Forest Laboratories, Inc.; Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
2. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
3. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
4. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
5. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
6. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
7. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
8. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
9. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
10. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
11. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 /PRNewswire-iReach/ -- Market Research Report ... 2009-2019 is a professional and in-depth market ... industry. The report firstly reviews the basic ... application and manufacturing technology. The report then ... Oxybutynin Hydrochloride listing their product specification, capacity, ...
(Date:9/19/2014)... 2014 Research and ... addition of the "Global Gynecological Devices ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... into wide categories based on their operations. ... of different gynecological conditions that affect the ...
(Date:9/19/2014)... , September 19, 2014 ... Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture ... Users (Hospitals), Advanced technologies - Global Forecast to ... is poised to reach $19,786.3 Million by 2019 ... of 6.8% from 2014 to 2019. ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2011 on Monday, May 9, 2011. A press release announcing ... trading. (Logo:   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the first quarter ended March ...
... Measuring the body temperatures of newborns with temporal artery ... by axillary (under arm) thermometry, the clinically recommended method ... to a new study reported in Advances in ... first published clinical analysis evaluating the accuracy of temporal ...
Cached Medicine Technology:Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011 2Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011 3Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns 2Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns 3
(Date:9/20/2014)... September 20, 2014 The excitement is building up ... Airy, North Carolina. This year the Surry Arts Council will ... from around the country who are still fans of the Andy ... a sitcom that aired on CBS from 1960 through 1968. ... in American television history. Mount Airy, North Carolina is where ...
(Date:9/20/2014)... New York, NY (PRWEB) September 20, 2014 ... million of their customers may have had their credit card ... late last year, spawning a slew of headline articles ... but those weren’t the only eye opening numbers. , ... numbers were stolen, almost like it’s a way to score ...
(Date:9/20/2014)... 20, 2014 The first federal bellwether ... in its third week in the U.S. District Court, ... Court documents indicate that the week opened in ... from a DePuy Orthopaedics vice president, who discussed the ... company’s Pinnacle hip replacement. According to Reuters, the executive ...
(Date:9/19/2014)... 2014 Consistent premium price increases ... Vision Insurance industry in recent years; however, costs ... industry margins. From 2009 to 2014, industry revenue ... coverage for routine eye exams and other procedures, ... lens and refractive surgery. According to IBISWorld Industry ...
(Date:9/19/2014)... News) -- As kids transition from elementary to middle ... to a recent study. But the researchers ... that verbal and physical bullying declines as students get ... prevention strategies must address all types of bullying as ... the researchers said. The study was published recently in ...
Breaking Medicine News(10 mins):Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News: Cyberbullying Seems to Ramp Up in Middle School 2
... Unit in Leeds receives Lilly,s 2008 Global ... ... Inc. (NYSE:,CVD), a leading provider of drug development services, today announced ... Lilly and Company., Covance,s clinical research unit based in Leeds, ...
... According to recent,reporting, including today,s Washington ... is circulating a draft proposed,regulation that, if ... providers to withhold the critical health care ... about their care. As a leading health,care ...
... Data for Second ... Quarter 2008 ... July 31 Sunrise Senior Living,Inc. (NYSE: SRZ ) today announced that ... the Securities and Exchange Commission,("SEC"). The Company also reported preliminary selected financial and,operating ...
... in chronic kidney cases , , THURSDAY, July 31 (HealthDay ... routinely measured marker of bone disease -- may signal ... for chronic kidney disease, say U.S. researchers. , The ... a three-year period. It found that patients with alkaline ...
... Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical company ... that it will release financial results for the ... market open on Friday, August 8, 2008., ... Gregory Frost,PhD, Vice President and Chief Scientific Officer, ...
... WEST CHESTER, Ohio, July 31 AtriCure, Inc.,(Nasdaq: ATRC ), ... today announced that it will present at the following,investor conferences during ... August 6, 2008 at the Millennium Broadway ... and Chief Executive Officer, is scheduled to present at 9:00 ...
Cached Medicine News:Health News:Covance Recognized for Outstanding Customer Service by Eli Lilly and Company 2Health News:SPOKESPERSON AVAILABILTY: Planned Parenthood President Available for Interviews on Proposed HHS Regulations 2Health News:Sunrise Files 2007 Form 10-K 2Health News:Sunrise Files 2007 Form 10-K 3Health News:Sunrise Files 2007 Form 10-K 4Health News:Sunrise Files 2007 Form 10-K 5Health News:Sunrise Files 2007 Form 10-K 6Health News:Sunrise Files 2007 Form 10-K 7Health News:Sunrise Files 2007 Form 10-K 8Health News:Sunrise Files 2007 Form 10-K 9Health News:Sunrise Files 2007 Form 10-K 10Health News:Sunrise Files 2007 Form 10-K 11Health News:Bone Disease Test Shows Death Risk for Dialysis Patients 2Health News:Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8 2Health News:AtriCure to Present at the BMO Focus on Healthcare and Canaccord Adams Global Growth Conferences in August 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: